LM364NCT07847905
A Phase I/II of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
StatusEnrolling by Invitation
PhasePhase 1/2
SponsorLaNova Medicines Limited
Primary completion (estimated)
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Enrolling by invitation only
- Start date changed from estimate of Oct 19, 2026 to Oct 20, 2026
- Study sites: 8 to 7
- Notable Primary endpoint(s) modified
- Secondary endpoints: 39 to 38
- Study title shortened, about 1 word
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Dose limiting toxicity (DLT)
Timeframe: 78 Weeks
Adverse events (AEs)
Timeframe: 78 weeks
serious adverse events (SAEs)
Timeframe: 78 weeks
Temperatures
Timeframe: 78 weeks
Pulse in BPM
Timeframe: 78 weeks
Blood Pressure in mmHg
Timeframe: 78 weeks
Weight in Kg
Timeframe: 78 weeks
Height in centimeter
Timeframe: 78 weeks
Laboratory examinations--Blood Routine examination-Complete Blood Count
Timeframe: 78 weeks
Laboratory examinations--Blood biochemistry- Electrolytes and Metabolic Parameters
Timeframe: 78 weeks
Laboratory examinations-Urine Routine test-Urinalysis
Timeframe: 78 weeks
Laboratory examinations--Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)
Timeframe: 78 weeks
Laboratory examinations--Thyroid function-For the detection of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxine (FT4)
Timeframe: 78 weeks
Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage
Timeframe: 78 weeks
12-lead electrocardiogram (ECG) in HR
Timeframe: 78 weeks
12-lead electrocardiogram (ECG) in RR
Timeframe: 78 weeks
12-lead electrocardiogram (ECG) in PR
Timeframe: 78 weeks
12-lead electrocardiogram (ECG) in QRS
Timeframe: 78 weeks
12-lead electrocardiogram (ECG) in QT
Timeframe: 78 weeks
12-lead electrocardiogram (ECG) in QTcF
Timeframe: 78 weeks
ECOG score-Cooperative Oncology Group score
Timeframe: 78 weeks
Objective Response Rate (ORR)
Timeframe: 52 weeks
Secondary (38)
PK Parameter: Area Under the Concentration-time Curve(AUC)
Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)
PK Parameter:Time of Maximum Observed Concentration (Tmax)
PK Parameter: Elimination Half-life (T1/2)
PK Parameter: Steady State Maximum Concentration(Cmax,ss)
Show 33 moreShow less
PK Parameter: Steady State Minimum Concentration(Cmin,ss)
PK Parameter: Systemic Clearance at Steady State (CLss)
PK Parameter: Volume of Distribution at Steady-State (Vss)
PK Parameter: Accumulation Ratio (Rac)
PK Parameter: Degree of Fluctuation (DF)
Immunogenicity testing-Anti-drug antibody
Immunogenicity testing-neutralizing antibody (Nab)
Objective response rate (ORR)
Duration of response (DOR)
Disease control rate (DCR = CR + PR + SD)
Progression free survival according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
Overall survival (OS)
Changes of target lesions from baseline in Millimeter
QTc-PK relationship -> Correlation concentrations (total antibody, free DXd) vs ΔQTcF (Fridericia's correction)
Incidence of adverse events (AEs)
Incidence of serious adverse events (SAEs)
Temperature (Celsius)
Pulse in BPM(Beat per Minute)
Blood Pressure in mmHg
Weight in Kg
Height in centimeters
Laboratory examinations--Blood Routine examination-Complete Blood Count
Laboratory tests-Urine Routine test-Urinalysis
Laboratory tests-Blood biochemistry- Electrolytes and Metabolic Parameters
Laboratory tests- Coagulation function-For the detection of Prothrombin time (PT), Activated partial thromboplastin time (APTT)
Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage
12-lead electrocardiogram (ECG) in HR
12-lead electrocardiogram (ECG) in RR
12-lead electrocardiogram (ECG) in PR
12-lead electrocardiogram (ECG) in QRS
12-lead electrocardiogram (ECG) in QT
12-lead electrocardiogram (ECG) in QTcF
Eastern Cooperative Oncology Group score
Arms and interventions
LM-364 MonotherapyExperimental
LM-364 Combination TherapyExperimental
Drugs: LM-364 for injection, Tislelizumab
Sites
7 sites in 1 country